PURPOSE: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. METHODS: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. RESULTS: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. RECOMMENDATIONS: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.
PURPOSE: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. METHODS: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. RESULTS: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. RECOMMENDATIONS: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.
Authors: Patrick L Fitzgibbons; Douglas A Murphy; M Elizabeth H Hammond; D Craig Allred; Paul N Valenstein Journal: Arch Pathol Lab Med Date: 2010-06 Impact factor: 5.534
Authors: Meredith M Regan; Giuseppe Viale; Mauro G Mastropasqua; Eugenio Maiorano; Rastko Golouh; Antonino Carbone; Bob Brown; Mart Suurküla; Gerald Langman; Luca Mazzucchelli; Stephen Braye; Piergiovanni Grigolato; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Alan S Coates; Aron Goldhirsch; Barry Gusterson Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 13.506
Authors: Giuseppe Viale; Meredith M Regan; Eugenio Maiorano; Mauro G Mastropasqua; Rastko Golouh; Tiziana Perin; Robert W Brown; Anikó Kovács; Komala Pillay; Christian Ohlschlegel; Stephen Braye; Piergiovanni Grigolato; Tiziana Rusca; Richard D Gelber; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Barry A Gusterson; Alan S Coates Journal: J Clin Oncol Date: 2008-03-20 Impact factor: 44.544
Authors: Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred Journal: Mod Pathol Date: 2004-12 Impact factor: 7.842
Authors: Sunil S Badve; Frederick L Baehner; Robert P Gray; Barrett H Childs; Tara Maddala; Mei-Lan Liu; Steve C Rowley; Steven Shak; Edith A Perez; Edith D Perez; Lawrence J Shulman; Silvana Martino; Nancy E Davidson; George W Sledge; Lori J Goldstein; Joseph A Sparano Journal: J Clin Oncol Date: 2008-05-20 Impact factor: 44.544
Authors: Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam Journal: Ann Surg Oncol Date: 2011-09-27 Impact factor: 5.344